Colon Cancer Clinical Trials

CLINICAL TRIAL 16028
Transdisciplinary Research in Colorectal Cancer: The ColoCare Study
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 21336
A Phase I/Ib Global, Multicenter, Open-Label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (Intrinsic)
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); Bevicizumab (); Cetuximab (); Divarasib (); Erbitux (Cetuximab); FOLFIRI (); FOLFOX (); GDC-6036 (); Inavolisib (); Oxaliplatin (); SY-5609 (); Tiragolumab (); eloxatin (Oxaliplatin); leucovorin ()

CLINICAL TRIAL 21459
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); CAPOX (); CPT-11 (irinotecan); Camptosar (irinotecan); FOLFIRINOX (); FOLFOX6 (); Oxaliplatin (); Xeloda (capecitabine); capecitabine (); eloxatin (Oxaliplatin); irinotecan (); leucovorin ()

CLINICAL TRIAL 21589
BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing
Condition: Immunotherapy
Intervention:

CLINICAL TRIAL 21641
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF_ Fusion Protein BCA101 Alone and in Combination with Pembrolizumab in Patients With EGFR-Driven Advanced Solid Tumors
Condition: Head & Neck
Intervention: BCA101 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23064
Phase 1 Single Center Study to Evaluate Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Single Agent Mitomycin C (MMC) in Peritoneal Carcinomatosis (PC) from Solid Gastrointestinal Malignancies (sGI-PC) in Palliative Setting
Condition: Gastrointestinal Tumor
Intervention: Fluorouracil (); leucovorin (); mitomycin c ()

CLINICAL TRIAL 23188
A Phase II Study of Enfortumab Vedotin in Patients with Advanced or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
Condition: Gastrointestinal Tumor
Intervention: Enfortumab Vedotin (Padcev)

CLINICAL TRIAL 23309
A Platform Study of RAS(ON) Inhibitors to Treat Patients with Gastrointestinal Solid tumor - SUB-A: Study of RMC-6236 in Combination with 5-flourouracil-based regimens in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma, - SUB: Study of RMC-6236 in Combination with Cetuximab with or without mFOLFOX6 in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma, - SUB-C: Study of RMC-6236 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma - SUB-D: Study of RMC-9805 with or without RMC-6236 in Combination with 5-flourouracil-based Therapies in Patients with RAS G12D-Mutant Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma - SUB-E: Study of RMC-9805 with or without RMC-6236 in Combination with Cetuximab-based Therapies in Patients with RAS G12D-Mutant Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma - SUB-F: Study of RMC-9805 With or Without RMC-6236 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with RAS G12D-Mutant Metastatic Pancreatic Ductal Adenocarcinoma
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); Avastin (Bevacizumab); Bevacizumab (); CPT-11 (irinotecan); Camptosar (irinotecan); Cetuximab (); Daraxonrasib (); Erbitux (Cetuximab); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); RMC-6236 (Daraxonrasib); RMC-9805 (Zoldonrasib); Zoldonrasib (); eloxatin (Oxaliplatin); gemcitabine (); irinotecan (); leucovorin (); mFOLFIRINOX (); mFOLFOX6 ()

CLINICAL TRIAL 23448
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients with Solid Tumors with KRASG12D Mutation
Condition: Multiple
Intervention: Cemiplimab (); Cetuximab (); Erbitux (Cetuximab); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Pembrolizumab (Keytruda); QTX3034 (); REGN2810 (Cemiplimab); gemcitabine (); mFOLFOX6 ()

CLINICAL TRIAL 23464
ColoCare GO
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 23549
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); VET3-TGI ()

CLINICAL TRIAL 23585
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)
Condition: Breast
Intervention: Avastin (Bevacizumab); BBO-10203 (); Bevacizumab (); FOLFOX (); Faslodex (fulvestrant); Herceptin (Trastuzumab); LEE011 (Ribociclib); Ribociclib (); Trastuzumab (); fulvestrant (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 23599
Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers
Condition: Multiple
Intervention: Alimta (Pemetrexed); BBO-10203 (); BBO-11818 (); Cetuximab (); Erbitux (Cetuximab); FOLFOX (); Gemzar (gemcitabine); NALIRIFOX (); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin (); cisplatin (); gemcitabine (); mFOLFIRINOX (); mFOLFOX6 ()

CLINICAL TRIAL 23553
DENALI-1: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod CAR T, in Heterozygous HLA A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA A*02 Expression.
Condition: Immunotherapy
Intervention: A2B395 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23625
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)
Condition: Gastrointestinal Tumor
Intervention: Telisotuzumab Adizutecan ()

CLINICAL TRIAL 23660
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention:

CLINICAL TRIAL 23728
An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab Versus Trifluridine-tipiracil plus Bevacizumab Alone in Patients with Refractory Metastatic Colorectal Cancer with Liver Dominant Disease
Condition: Gastrointestinal Tumor
Intervention: Alkeran (Melphalan); Avastin (Bevacizumab); Bevacizumab (); Melphalan (); Tipiracil (); Trifluridine ()

CLINICAL TRIAL 23786
Unusual Causes of Familial and Early-Onset Cancer
Condition: Multiple
Intervention:

CLINICAL TRIAL 23766
A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: FID-022 ()

CLINICAL TRIAL 23787
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Condition: Multiple
Intervention: ALX2004 ()

CLINICAL TRIAL 23829
A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants with Unresectable Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: TAK-505 ()

CLINICAL TRIAL 23924
Blood-Based Biomarkers for the Minimally-Invasive Detection of Colorectal Cancer
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 23993
A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients with Relapsed or Refractory Advanced Solid Tumors
Condition: Multiple
Intervention: IMGS-001 ()

CLINICAL TRIAL 23965
A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: BH3120 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23967
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); CPT-11 (irinotecan); Camptosar (irinotecan); Oxaliplatin (); Pumitamig / Bevacizumab (); Xeloda (capecitabine); capecitabine (); eloxatin (Oxaliplatin); irinotecan (); leucovorin ()

CLINICAL TRIAL 23990
AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer
Condition: Gastrointestinal Tumor
Intervention: Avastin (Bevacizumab); Bevacizumab (); Telisotuzumab Adizutecan (); Trifluridine + Tipiracil ()

CLINICAL TRIAL 24028
OMNIRAY, A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults with GRPR-Positive Advanced Solid Tumors
Condition: Multiple
Intervention: Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Imlunestrant (); LY2835219 (Abemaciclib); LY4257496 (); LY4257529 (); Letrozole (); Xeloda (capecitabine); capecitabine (); fulvestrant ()

CLINICAL TRIAL 24059
Master Data and Biospecimen Collection Protocol to Improve Outcomes for Young Adults with Gastrointestinal Cancer
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 24071
Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients with Advanced KRAS G12V-Mutant Solid Tumors
Condition: Multiple
Intervention: Cetuximab (); Daraxonrasib (); Erbitux (Cetuximab); RMC-5127 (); RMC-6236 (Daraxonrasib)

CLINICAL TRIAL 24082
Using Automated Biochips to Assist in Specific Chemotherapy Selection in Pancreatic and Colorectal Cancer Patients
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 24095
Phase 1/2a Open-Label Clinical Trial Evaluating VBC101, an EGFR and cMET Targeted Bi-Specific Antibody Drug Conjugate, in Participants With Advanced Solid Tumor Malignancies
Condition: Multiple
Intervention: VBC101 ()

CLINICAL TRIAL 24103
A First-in-Human Phase 1 Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation
Condition: Multiple
Intervention: KST-6051 ()

CLINICAL TRIAL 24190
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)
Condition: Multiple
Intervention: LY4337713 (); [18F] FAPI-74 (); [Ga-68]-FAPI-46 ()

CLINICAL TRIAL 24229
Defining the Effects of Cytoreductive Surgery and HIPEC on the Tumor Microenvironment
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 24236
A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: 5-fluorouracil (); Alimta (Pemetrexed); ERAS-0015 (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); Panitumumab (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxotere (docetaxel); Vectibix (Panitumumab); carboplatin (); cisplatin (); docetaxel (); eloxatin (Oxaliplatin); gemcitabine (); leucovorin ()

CLINICAL TRIAL 24258
A Phase 1 Study to Evaluate the Safety and Efficacy of DISP-10 in Participants with Advanced Gastrointestinal Cancers
Condition: Immunotherapy
Intervention: Cyclophosphamide (); DV-10 (); Fludarabine (); Idecabtagene Vicleucel ()

CLINICAL TRIAL 24278
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); Cetuximab (); Erbitux (Cetuximab); Oxaliplatin (); Panitumumab (); VS-7375 (); Vectibix (Panitumumab); eloxatin (Oxaliplatin); leucovorin ()

CLINICAL TRIAL 24299
A study of a mutant-selective inhibitor, CGT6297, in patients with advanced solid tumors harboring PIK3CA mutations
Condition: Multiple
Intervention: CGT6297 ()

CLINICAL TRIAL 24394
A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN9025 in Participants with Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Condition: Multiple
Intervention: AN9025 ()